FRANKLIN LAKES, N.J., Apr. 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications.
BD’s patented stochastic labelling technology incorporating molecular indexes (known also as UMIs or molecular barcodes), enables the precise counting of individual biological molecules, including DNA or RNA, in complex and often volume-limited samples. BD is developing a suite of products utilizing this technology for accurate quantitative measurements of mRNA targets from single cells, enabling researchers to gain greater insights into the biology of complex and heterogeneous samples.
BD is also working with additional partners to license this technology and enable the development of novel tools and assays for the scientific community. “Stochastic labelling with molecular indexes is a simple, yet powerful, approach for the accurate quantification of target molecules in complex biological samples,” said Stephen Gunstream, vice president of Genomics at BD. “This technology enables a range of future products that will broadly benefit many areas of research and future clinical applications."
Specific financial terms of the agreement have not been disclosed.
For additional information, including inquiries regarding licensing of these technologies, contact BD at +1 650-665-2400.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com